Squarepoint’s UroGen Pharma URGN Stock Holding History

Squarepoint’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$431K	Buy	+11,699	New	+$317K	﹤0.01%	3536
2026 Q1	–	Sell	-22,831	Closed	-$535K	–	5014
2025 Q4	$535K	Buy	+22,831	New	+$495K	﹤0.01%	3159
2025 Q3	–	Sell	-94,309	Closed	-$1.29M	–	5032
2025 Q2	$1.29M	Buy	94,309 +61,545	+188%	+$591K	﹤0.01%	2451
2025 Q1	$362K	Sell	32,764 -17,430	-35%	-$186K	﹤0.01%	3587
2024 Q4	$535K	Sell	50,194 -57,451	-53%	-$688K	﹤0.01%	3671
2024 Q3	$1.37M	Buy	+107,645	New	+$1.6M	﹤0.01%	2361
2024 Q2	–	Sell	-63,039	Closed	-$946K	–	4682
2024 Q1	$946K	Buy	63,039 +3,349	+6%	+$54.7K	﹤0.01%	2640
2023 Q4	$895K	Buy	+59,690	New	+$775K	﹤0.01%	2602
2023 Q3	–	Sell	-10,920	Closed	-$113K	–	4272
2023 Q2	$113K	Buy	+10,920	New	+$120K	﹤0.01%	3344
2021 Q3	–	Sell	-21,554	Closed	-$329K	–	3449
2021 Q2	$329K	Buy	+21,554	New	+$390K	﹤0.01%	2460
2019 Q4	–	Sell	-9,289	Closed	-$221K	–	2827
2019 Q3	$221K	Buy	9,289 +3,220	+53%	+$105K	﹤0.01%	2040
2019 Q2	$218K	Sell	6,069 -7,171	-54%	-$264K	﹤0.01%	2076
2019 Q1	$489K	Buy	+13,240	New	+$555K	0.01%	1495

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Squarepoint's URGN Position: Q2 2026 in Review

Squarepoint opened a new position in UroGen Pharma (URGN) in Q2 2026: 11,699 shares worth $431K. The stake represents ﹤0.01% of the portfolio and ranks #3536 among its holdings. This is a return to the name: Squarepoint previously reported a position in URGN as recently as Q4 2025.

Squarepoint first reported a position in URGN in Q1 2019 and has held it in 13 quarters since. The position peaked at $1.37M in Q3 2024. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Squarepoint held 11,699 shares of UroGen Pharma worth $431K as of Q2 2026.
UroGen Pharma was a new Squarepoint position in Q2 2026.
UroGen Pharma made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3536 holding.
Squarepoint first reported a position in UroGen Pharma in Q1 2019 and has held it in 13 quarters since.
Squarepoint's UroGen Pharma position peaked at $1.37M in Q3 2024.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.